All patients expressed BCL3, with six of the patients expressing four times or more the amount compared to the patient with the lowest expression level, confirming the Affymetrix data showing that a subset of MM patients expresses high amounts of BCL3. Expression of Bcl-3 at protein level was examined by two independent methods, immunohistochemistry in bone marrow biopsies and Western blot of purified myeloma cells. The gene discussed is BCL3; the disease is plasma cell myeloma.